Two Doses of Pfizer-BioNTech Prove Highly Effective at Preventing COVID-19 Hospitalizations in Adolescents

The CDC found 2 doses of Pfizer-BioNTech reduced COVID-19 severe outcomes and hospitalization by 93% in adolescents 12-18 years old.

The CDC found 2 doses of Pfizer-BioNTech to be highly effective against COVID-19 severe outcomes and hospitalization in adolescents 12-18 years old.

There is a heavy focus on how COVID-19 causes higher rates of severe disease and mortality in older adults, but there is limited data on the real-world efficacy of vaccines in adolescents (12-18 years of age).

New research released today by the Centers for Disease Control and Prevention (CDC) examined the effectiveness of 2 doses of the mRNA Pfizer-BioNTech vaccine against hospitalizations in 12-18-year-olds.

The study ran from June-September 2021, and investigators included 464 fully vaccinated (with Pfizer-BioNTech) or fully unvaccinated patients (having received no doses of any COVID-19 vaccine) in 19 pediatric hospitals. Of these, 179 were case-patients and 285 were controls. According to the CDC’s Morbidity and Mortality Weekly Report, “Case-patients were hospitalized with symptomatic COVID-19–like illness and a positive SARS-CoV-2 reverse transcription–polymerase chain reaction (RT-PCR) or antigen test result; no case-patients received a diagnosis of multisystem inflammatory syndrome in children (MIS-C) during their enrolling hospitalization. Two hospitalized control groups were enrolled: 1) patients with symptoms compatible with COVID-19 with negative SARS-CoV-2 RT-PCR or antigen test results (test-negative) and 2) patients without COVID-19–associated symptoms who might or might not have received SARS-CoV-2 testing (syndrome-negative).”

The median age of the case-patients and controls was 15 years, 72% had at least one underlying condition, and 68% attended school in-person. The average length of hospital stay was 5 days among unvaccinated patents and 3 days for vaccinated patients.

Among the 179 case-patients, 6 (3%) were vaccinated and 173 (97%) were unvaccinated. 77 (43%) case-patients were admitted to the intensive care unit (ICU), 29 (16%) became critically ill, and 2 (7%) died. All case-patients who were admitted to the ICU, became critically ill, and died were unvaccinated.

Among the hospitalized 12–18-year-olds, 97% were unvaccinated. This confirms the importance of vaccinations and disproves prior assumptions that children, adolescents, and young adults could not become severely ill upon contracting COVID-19.

All patients studied were hospitalized in this real-world analysis, and full vaccination reduced the risk of hospitalization of persons 12-18 years old by 93%. Notably, this study was conducted while Delta (B.1.617.2) was the predominant variant, proving the Pfizer-BioNTech vaccine remained effective even against this more infectious strain. These results were consistent with other studies conducted by Pfizer-BioNTech and other unaffiliated researchers.

The CDC expressed confidence in the success of vaccinating adolescents, and is expected to move on approving vaccinations for even younger children.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.